FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085129277> ?p ?o ?g. }

• W2085129277 endingPage "2157" @default.
• W2085129277 startingPage "2148" @default.
• W2085129277 abstract "Abstract BACKGROUND CD40 plays a critical role in immunoregulation, and CD40 ligation is being investigated as a therapy for hematologic malignancies. Although soluble CD40 (sCD40) is a potential modulator of both antitumor responses and CD40‐based therapies, the levels and significance of sCD40 in patients with hematologic malignancies are unknown. METHODS The authors evaluated serum/plasma sCD40 levels using an enzyme‐linked immunoassay in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and multiple myeloma (MM). RESULTS Levels of sCD40 were elevated in serum (>1.697 ng/mL) or plasma (>0.649 ng/mL) from 73% of patients with CLL, 80% of patients with MCL, 40% of patients with AML, 43% of patients with MDS, and 33% of patients with MM. Multivariate analysis of patients with MM demonstrated that elevated sCD40 was a significant, independent predictor of poor survival. In multivariate analysis of patients with AML, sCD40 was a significant prognostic factor when the interaction of age and sCD40 was included as a variable. Further analysis demonstrated that elevated sCD86 levels were associated with significantly shorter survival only in AML patients younger than age 64 years. Release of sCD40 by CLL cells was induced by cross‐linking with CD40 monoclonal antibody. CONCLUSIONS Many patients with hematologic malignancies have elevated circulating levels of sCD40, and these elevated levels are associated with a poor prognosis at least in patients with MM and AML, suggesting that sCD40 may have a role in modulating antitumor responses and also may be a useful prognostic marker. In addition, the findings suggested that further studies will be required to determine the effect of circulating sCD40 on the clinical effectiveness of CD40‐ligating reagents used in the treatment of hematologic malignancies. Cancer 2006. © 2006 American Cancer Society." @default.
• W2085129277 created "2016-06-24" @default.
• W2085129277 creator A5001420476 @default.
• W2085129277 creator A5001610010 @default.
• W2085129277 creator A5026834152 @default.
• W2085129277 creator A5027800341 @default.
• W2085129277 creator A5032055781 @default.
• W2085129277 creator A5061285204 @default.
• W2085129277 creator A5062740596 @default.
• W2085129277 creator A5080904561 @default.
• W2085129277 creator A5084379902 @default.
• W2085129277 date "2006-04-27" @default.
• W2085129277 modified "2023-10-15" @default.
• W2085129277 title "Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies" @default.
• W2085129277 cites W1517873264 @default.
• W2085129277 cites W1553698258 @default.
• W2085129277 cites W1589878968 @default.
• W2085129277 cites W1876800744 @default.
• W2085129277 cites W1964181260 @default.
• W2085129277 cites W1968052999 @default.
• W2085129277 cites W1979696790 @default.
• W2085129277 cites W1989247115 @default.
• W2085129277 cites W1998309406 @default.
• W2085129277 cites W2011423376 @default.
• W2085129277 cites W2023155608 @default.
• W2085129277 cites W2041304401 @default.
• W2085129277 cites W2050912734 @default.
• W2085129277 cites W2082203090 @default.
• W2085129277 cites W2083849942 @default.
• W2085129277 cites W2094371537 @default.
• W2085129277 cites W2096158777 @default.
• W2085129277 cites W2101492664 @default.
• W2085129277 cites W2120474651 @default.
• W2085129277 cites W2150402162 @default.
• W2085129277 cites W2317255301 @default.
• W2085129277 cites W4251148107 @default.
• W2085129277 cites W899734449 @default.
• W2085129277 doi "https://doi.org/10.1002/cncr.21816" @default.
• W2085129277 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16598754" @default.
• W2085129277 hasPublicationYear "2006" @default.
• W2085129277 type Work @default.
• W2085129277 sameAs 2085129277 @default.
• W2085129277 citedByCount "47" @default.
• W2085129277 countsByYear W20851292772012 @default.
• W2085129277 countsByYear W20851292772013 @default.
• W2085129277 countsByYear W20851292772014 @default.
• W2085129277 countsByYear W20851292772015 @default.
• W2085129277 countsByYear W20851292772016 @default.
• W2085129277 countsByYear W20851292772017 @default.
• W2085129277 countsByYear W20851292772019 @default.
• W2085129277 countsByYear W20851292772020 @default.
• W2085129277 countsByYear W20851292772021 @default.
• W2085129277 countsByYear W20851292772022 @default.
• W2085129277 countsByYear W20851292772023 @default.
• W2085129277 crossrefType "journal-article" @default.
• W2085129277 hasAuthorship W2085129277A5001420476 @default.
• W2085129277 hasAuthorship W2085129277A5001610010 @default.
• W2085129277 hasAuthorship W2085129277A5026834152 @default.
• W2085129277 hasAuthorship W2085129277A5027800341 @default.
• W2085129277 hasAuthorship W2085129277A5032055781 @default.
• W2085129277 hasAuthorship W2085129277A5061285204 @default.
• W2085129277 hasAuthorship W2085129277A5062740596 @default.
• W2085129277 hasAuthorship W2085129277A5080904561 @default.
• W2085129277 hasAuthorship W2085129277A5084379902 @default.
• W2085129277 hasBestOaLocation W20851292771 @default.
• W2085129277 hasConcept C126322002 @default.
• W2085129277 hasConcept C143998085 @default.
• W2085129277 hasConcept C154317977 @default.
• W2085129277 hasConcept C185592680 @default.
• W2085129277 hasConcept C202751555 @default.
• W2085129277 hasConcept C203014093 @default.
• W2085129277 hasConcept C2776364478 @default.
• W2085129277 hasConcept C2777938653 @default.
• W2085129277 hasConcept C2778461978 @default.
• W2085129277 hasConcept C2778729363 @default.
• W2085129277 hasConcept C39347974 @default.
• W2085129277 hasConcept C55493867 @default.
• W2085129277 hasConcept C71924100 @default.
• W2085129277 hasConcept C90924648 @default.
• W2085129277 hasConceptScore W2085129277C126322002 @default.
• W2085129277 hasConceptScore W2085129277C143998085 @default.
• W2085129277 hasConceptScore W2085129277C154317977 @default.
• W2085129277 hasConceptScore W2085129277C185592680 @default.
• W2085129277 hasConceptScore W2085129277C202751555 @default.
• W2085129277 hasConceptScore W2085129277C203014093 @default.
• W2085129277 hasConceptScore W2085129277C2776364478 @default.
• W2085129277 hasConceptScore W2085129277C2777938653 @default.
• W2085129277 hasConceptScore W2085129277C2778461978 @default.
• W2085129277 hasConceptScore W2085129277C2778729363 @default.
• W2085129277 hasConceptScore W2085129277C39347974 @default.
• W2085129277 hasConceptScore W2085129277C55493867 @default.
• W2085129277 hasConceptScore W2085129277C71924100 @default.
• W2085129277 hasConceptScore W2085129277C90924648 @default.
• W2085129277 hasIssue "10" @default.
• W2085129277 hasLocation W20851292771 @default.
• W2085129277 hasLocation W20851292772 @default.
• W2085129277 hasOpenAccess W2085129277 @default.
• W2085129277 hasPrimaryLocation W20851292771 @default.

• next